Nowadays, influenza antigen detection test kits are used most frequently to detect influenza A or B virus to establish the diagnosis of influenza rapidly and initiate appropriate therapy. This study was conducted to evaluate the performance of the actim Influenza A&B test (Medix Biochemica). Overall, 473 respiratory specimens were analysed in the actim Influenza A&B test and the results were compared with those from an RT-PCR assay; 461 of these samples originated from paediatric patients aged 7 weeks to 6.5 years either with influenza-related symptoms or from the intensive care unit, and 12 samples originated from adults with underlying lung or haematological diseases. Diagnosis of influenza A or B virus could be established using the actim Influenza A&B test (9/473 samples for influenza A virus and 6/473 for influenza B virus). RT-PCR revealed 23 patients with influenza virus (13/473 for influenza A virus and 10/473 for influenza B virus). The sensitivity and specificity of the actim Influenza A&B test were 65 and 100 % compared with the RT-PCR assay. However, 32 external quality assessment samples containing seven different strains of influenza A subtypes H1N1 and H3N2 and the avian H5N1 were detected correctly by the actim Influenza A&B test. No cross-reactivity to a range of bacterial, fungal and other viral pathogens was observed. In conclusion, the actim Influenza A&B test is reliable for positive results due to its high specificity. Nevertheless, negative results from this test need to be confirmed by a more sensitive assay because of the low sensitivity observed with diagnostic samples.
INTRODUCTION
Influenza viruses cause significant morbidity and mortality in both children and adults (Heikkinen, 2006; van der Wouden et al., 2006) during local outbreaks or epidemics. Outbreaks and epidemics may appear at any time but are usually concentrated in the winter months in countries with temperate climates (Brammer, 2002) .
The rapid detection of influenza viruses is important to apply preventative strategies, initiate antiviral therapy, detect avian influenza viruses and exclude influenza-like bacterial and viral diseases (e.g. anthrax, smallpox). Moreover, it is important to determine not only whether influenza virus is present, but also which type of influenza virus is present (Noyola et al., 2000a; Chan et al., 2002; Effler et al., 2002; Poehling et al., 2002) .
Although the gold standard reference method for the diagnosis of influenza is isolation of the virus, commercially available rapid antigen detection tests have the advantage of providing results much more quickly, i.e. within approximately 30 min. These tests, also referred to as near-patient or point-of-care tests, are mostly immunoassays that detect influenza virus antigen, although one test detects viral neuraminidase activity (Noyola et al., 2000b; Uyeki, 2003) .
They detect and distinguish between influenza A and B viruses, detect but do not distinguish between influenza A and B viruses or detect influenza A virus only. The tests vary in complexity, type of respiratory specimen acceptable for testing and the time needed to obtain results (Seno et al., 1990; Rodriguez et al., 2002; Uyeki, 2003; Hurt et al., 2007) .
The actim Influenza A&B test (Medix Biochemica) is a point-of-care test utilizing influenza-specific mAbs for rapid diagnosis and differentiation of influenza A and B viruses. The aim of this study was to conduct a prospective evaluation of this test for qualitative, simultaneous and differential detection of influenza A and B antigens in different respiratory specimens. For this purpose, the actim Influenza A&B test was compared with an established inhouse RT-PCR assay (Schweiger et al., 2000) for sensitivity, specificity and the time needed to obtain results.
METHODS
Viruses and other micro-organisms tested. The performance of the actim Influenza A&B test was assessed for human influenza A virus (H1N1, H3N2 and H5N1) and influenza B virus samples (n532) obtained from the quality assurance institution INSTAND , were used for this study. The age of the patients ranged from 7 weeks to 6.5 years with the majority (63 %) being between 0.5 and 1.5 years. Secretions were aspirated into a mucus trap by inserting a catheter into the nasopharynx of each nostril in turn. Specimens were collected at the time of admission and held at 4-8 uC (for periods of 1-6 h, depending on time of admission) until they were transported to the laboratory. Specimens collected more than 24 h prior to arrival in the laboratory were excluded from the study. Transport to the laboratory was carried out at ambient temperature; the maximal duration of exposure to ambient temperature was less than 3 h. Aliquots of the respiratory specimens were taken for RT-PCR assay of the respiratory viruses. A second aliquot was used for analysis in the actim Influenza A&B test and a third aliquot was frozen at 270 uC for resolution of discrepant results.
Additionally, 12 respiratory specimens (stored at 220 uC) collected from adults with underlying lung or haematological diseases who had tested positive for influenza virus were included in the panel of 473 samples.
Ethical approval was obtained from the institutional review boards for this study.
actim Influenza A&B test. The actim Influenza A&B test was carried out according to the manufacturer's instructions. The test was performed with the investigator blinded to the results of the RT-PCR. For liquid specimens, 300 ml sample was dispensed into the test tube together with three drops of extraction buffer, and nasopharyngeal swabs were inserted into test tubes containing six drops of NaCl buffer and three drops of extraction buffer, mixed and incubated for 5 min at room temperature to allow virus particles in the specimens to be disrupted, exposing internal viral nucleoproteins. The appearance of a blue-black control line on the actim test strip confirmed that the test had been performed properly and that the results were therefore valid.
is an immunochromatographic membrane assay that uses highly sensitive mAbs to detect influenza type A and B nucleoprotein antigens in nasopharyngeal specimens. The test was carried out according to the manufacturer's instructions.
RNA extraction and cDNA synthesis. Total viral RNA was extracted using a commercial kit (QIAamp Viral RNA kit; Qiagen) according to the manufacturer's instructions. Viral RNA was extracted from 140 ml of each sample. The RNA was eluted from columns with 50 ml RNase-free water (Qiagen) and used immediately in the following experiments or stored at 280 uC. cDNA synthesis was carried out at 37 uC for 1 h using 10 ml eluted RNA, 100 U murine leukaemia virus reverse transcriptase (Gibco/Invitrogen), 10 mM dithiothreitol, 20 U RNasin (Promega) and 0.25 mM random hexamer primers (Gibco/Invitrogen).
FastCycler PCR. PCR was carried out in a 20 ml volume containing 2.5 ml cDNA, 26 master mix (FastCycler 9800, 26 GeneAmp Fast PCR Master Mix; Applied Biosystems) and 0.25 mM each primer. Primer sets specific for influenza A and B virus (custom synthesized by MWG-Biotech) were used to detect and differentiate the two influenza viruses as described by Schweiger et al. (2000) . PCR conditions were initial denaturation at 95 uC for 10 s, 40 cycles of 95 uC for 2 s and annealing and extension at 67 uC for 15 s, and final extension at 72 uC for 7 min. Amplicons were detected by gel electrophoresis.
Statistical analysis. Specimens positive for influenza A or B virus in the RT-PCR were regarded as true positives. The sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of the actim Influenza A&B test results compared with those of the RT-PCR assay were calculated using two-by-two contingency tables.
RESULTS

Cross-reactivity of the actim Influenza A&B test
To determine the cross-reactivity of the antigen detection kit actim Influenza A&B, commensal and pathogenic micro-organisms (11 bacteria, 10 viruses and four Candida species) that may be present in the nasal cavity or nasopharynx were tested. All of the samples were negative by the actim Influenza A&B test.
Analytical sensitivity of the actim Influenza A&B test in quality assessment influenza samples A total of 32 quality assessment influenza A and B samples of different designation (INSTAND), including avian influenza virus, were evaluated by the actim Influenza A&B test and RT-PCR. All of these samples tested positive by both methods (Table 1) , revealing a sensitivity and specificity of 100 % for the actim Influenza A&B test.
Comparison of the actim Influenza A&B test and RT-PCR assay
Among the 473 specimens, nine (1.9 %) were antigenpositive for influenza A virus in the actim Influenza A&B test and 13 (2.8 %) were positive in the RT-PCR assay. Six specimens (1.3 %) were positive for influenza B virus by the actim Influenza A&B test and ten (2.1 %) in the RT-PCR assay (Table 2 ). All influenza samples that were detected by the actim Influenza A&B test were also positive in the RT-PCR assay.
The results for the first batch of PCR amplicons (n59) were confirmed by sequencing, whilst the other results were confirmed by haemagglutinin and neuraminidase genespecific PCR or by the use of other detection methods (virus culture, direct immunofluorescence, rapid antigen detection test or RT-PCR). Of the influenza A viruses detected, 11 were H3N2 and two were H1N1 (data not shown).
The overall sensitivity of the actim Influenza A&B test compared with the RT-PCR assay was 65.2 % (69.2 % for influenza A virus and 60 % for influenza B virus) with a specificity of 100 %. The actim Influenza A&B test revealed a PPV of 100 % (95 % CI 78.2-100 %) for both influenza virus types, whereas the NPV was approximately 98 % (95 % CI 96.5-99.2 %). 
Clinical symptoms of influenza A and B viruspositive cases
The majority of the influenza virus-positive samples were detected between February and March 2005 and between January and April 2008. Among the patients with influenza, the youngest was 7 weeks old and the eldest 61 years old (with influenza A and B virus, respectively; Table 3 ). The clinical presentation of the patients with influenza virus detection as well as the type of specimen in which influenza virus was detected are shown in Table  3 . No dual infections with influenza A and B viruses were detected. (Dunn et al., 2003) . The sensitivities of the different rapid assays for influenza virus available at present vary from 40 to 96 % among different studies, depending on the reference methods used (Noyola et al., 2000b; Herrmann et al., 2001; Chan et al., 2002; Effler et al., 2002; Poehling et al., 2002; Dunn et al., 2003; Hurt et al., 2007) .
For example, Herrmann et al. (2001) compared an optical immunoassay for rapid detection of influenza A and B virus with RT-PCR and immunofluorescence on nasopharyngeal aspirates and swabs. The sensitivity and specificity of the optical immunoassay in nasopharyngeal aspirates were 40.4 and 94.3 %, respectively, compared with the RT-PCR. In general, a greater yield of positive samples can be obtained with PCR techniques than with rapid antigen detection tests. This has been observed particularly when the sample is taken 3-4 days after the onset of symptoms, when the viral load drops sharply, as does the infecting capacity (Cherian et al., 1994) .
The Directigen FluA+B antigen test (BD Diagnostic Systems) was evaluated by Chan et al. (2002) in a study design similar to our present work. Most of the patients studied were children. Compared with an RT-PCR assay, the sensitivity, specificity, and PPV and NPV of the Directigen FluA+B test for influenza virus A were 96, 99.6, 96 and 99.6 %, and for influenza virus B were 87.5, 96.8, 80 and 98 %, respectively. In a French study of the QuickVue Influenza antigen test (Quidel), these values were 87.5, 100, 100 and 89.5 %, respectively (Arsene et al., 2004) . These results seem to suggest a better performance of the Directigen FluA+B and QuickVue Influenza (Table 2) . Therefore, the specificity and robustness of the actim Influenza A&B test are probably superior to those of the above-described rapid antigen detection kits.
As the sensitivity of the actim Influenza A&B assay in diagnostic samples seemed to be lower than that of the above-mentioned antigen detection kits (Table 1 ).
In summary, the studies cited above, together with our results, suggest that the reported sensitivities of influenza rapid antigen tests may vary highly in relation to the panel of diagnostic specimens tested. If a panel contains diagnostic specimens with low virus concentrations (perhaps because these were taken more than 2 days after the onset of symptoms), the sensitivities of antigen assays drop in comparison with that of RT-PCR, which can still detect influenza RNA due to its low detection limit. Thus RT-PCR offers an alternative method of diagnosing influenza virus infections. It has high sensitivity and specificity (Herrmann et al., 2001 ), but requires a high level of skill and a complex laboratory infrastructure, and takes several hours to perform, as was also shown in our study (150-170 min) . Therefore, RT-PCR does not fill the niche of tests that are rapid and easy to perform with a low level of expertise.
The low influenza activity in the Magdeburg area during the respective seasons between 2004 and 2008 was disadvantageous for this study, resulting in a limited number of positive specimens being obtained. Thus studying a larger number of positive specimens would make evaluation and determination of sensitivity and specificity more reliable. However, during times of low influenza incidence, the NPV of a rapid antigen detection test is higher and the PPV is lower than in times of high influenza activity (WHO, 2005) . Therefore, the high PPV of the actim assay observed in this study indicates that positive results do not need to be confirmed by RT-PCR and should be reported to the treating physician immediately in times of both low and high influenza incidence. However, negative actim Influenza A&B results, as well as negative results of other rapid antigen assays, should be confirmed by RT-PCR. This is even more important during the influenza season, because of decreasing NPV with increasing influenza virus incidence.
In conclusion, the actim Influenza A&B test is a rapid in vitro assay that detects and differentiates influenza A and B virus antigens (nucleoprotein) extracted from respiratory specimens. Because the actim Influenza A&B test is easy to perform and has a specificity and PPV of 100 % for each virus, this test is appropriate for acute cases as a first-line emergency diagnostic method. A negative result warrants confirmation with a more sensitive method.
